Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment.
第一作者:
Claudio,Festuccia
第一单位:
Department of Experimental Medicine, Chair of General Pathology, University of L'Aquila, Italy. festucci@univaq.it
作者:
主题词
动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);卡唑类(Carbazoles);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);药物疗法, 联合(Drug Therapy, Combination);呋喃类(Furans);男(雄)性(Male);小鼠(Mice);神经生长因子(Nerve Growth Factor);前列腺肿瘤(Prostatic Neoplasms);交叉感知受体(Receptor Cross-Talk);受体, trkA(Receptor, trkA);受体, 雄激素(Receptors, Androgen);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1002/pros.20884
PMID
19016477
发布时间
2021-12-03
- 浏览0

The Prostate
337-45页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文